Clinical experience with linezolid for the treatment of central nervous system infections.
about
Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciLinezolid for the treatment of Nocardia spp. infectionsPenetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.The first case of catheter-related bloodstream infection caused by Nocardia farcinica.Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis.Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.Linezolid for the treatment of patients with central nervous system infection.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.Therapy of community-acquired acute bacterial meningitis: the clock is running.Bacterial meningitis: new therapeutic approaches.Bacterial meningitis: an update of new treatment options.Sequential antimicrobial treatment with linezolid for neurosurgical infections: efficacy, safety and cost study.Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis in an experimental rabbit modelLinezolid cerebrospinal fluid concentration in central nervous system infection.Linezolid: a review of its properties, function, and use in critical care.
P2860
Q26853465-EB3C23A3-F8C6-43DA-9DAD-0C4DEDCFE2F4Q28245032-EFFB93E9-9A02-455D-BF51-2031A266DE64Q34142328-3657CF7E-82ED-44F6-A87A-261AB57A8613Q34255677-D92B5A47-29D2-4A61-855B-2500B89E69C5Q34299173-0A58D5E4-4522-4643-9DBE-8C644A199FD6Q35635671-E5637641-6B9C-4955-8D39-2B46E77C0079Q36281035-4F6CBE11-9023-466B-A509-85DEBA36528BQ36729811-2301730C-784E-428B-A492-2861D0FBDB3CQ36777850-B09DFE79-8BF1-4C9A-B617-0C73990CB6F6Q37077629-5272E001-0BD9-4D09-A5D4-0847100B1DEFQ37614552-43EE6D13-91B6-4AD0-BA19-A772997308C1Q38145360-97D77B20-BC47-4CBF-A107-4B28994FF1EBQ38570487-AAC7E309-A62E-4FE1-AF94-D1CD95FF8DCFQ40577600-40D3E0B4-659D-49F0-9195-8A0D553FF28BQ42288289-C4CC58BE-B985-4B6B-961E-6F783BA3F705Q48268927-B0D71EB4-9AEC-4027-B88A-5E35555A0AD0Q55368160-1455AB1E-E2D6-487E-A117-6F297E71669D
P2860
Clinical experience with linezolid for the treatment of central nervous system infections.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Clinical experience with linez ...... ral nervous system infections.
@en
Clinical experience with linez ...... ral nervous system infections.
@nl
type
label
Clinical experience with linez ...... ral nervous system infections.
@en
Clinical experience with linez ...... ral nervous system infections.
@nl
prefLabel
Clinical experience with linez ...... ral nervous system infections.
@en
Clinical experience with linez ...... ral nervous system infections.
@nl
P2860
P1476
Clinical experience with linez ...... ral nervous system infections.
@en
P2093
H-W Pfister
T A Rupprecht
P2860
P304
P356
10.1111/J.1468-1331.2005.01001.X
P577
2005-07-01T00:00:00Z